Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

ANKRD37 Inhibitors

The chemical class of ANKRD37 Inhibitors encompasses a diverse range of compounds designed to modulate the activity of ANKRD37, a protein characterized by ankyrin repeat domains known for mediating protein-protein interactions. This class of inhibitors is defined not by a shared chemical structure but by a functional objective: to influence ANKRD37's role in cellular processes, particularly those involving protein interactions and signaling pathways. The inhibitors operate through various mechanisms, each targeting different aspects of ANKRD37's activity or its interaction within the cellular environment. The primary focus of these compounds is to alter the molecular processes involving ANKRD37, either by affecting its ability to interact with other proteins or by modifying the conditions essential for its function in signaling pathways.

One approach within this class targets the protein-protein interaction capabilities of ANKRD37. Inhibitors designed for this purpose aim to disrupt the interactions mediated by the ankyrin repeats of ANKRD37, which are crucial for its presumed roles in cellular organization and signaling. By inhibiting these interactions, these compounds seek to disrupt the functional complexes that ANKRD37 forms with other proteins, affecting a range of cellular processes dependent on these protein interactions. Another approach involves targeting the signaling pathways in which ANKRD37 is thought to be involved. Since the regulation of protein-protein interactions and cellular signaling is often controlled by complex networks of signaling pathways, modulating these pathways can impact ANKRD37's function. This method of inhibition is based on altering the regulatory environment of ANKRD37, thus modifying its activity or interaction with other signaling components. The exploration of ANKRD37 Inhibitors is significant in the field of molecular biology, focusing on the modulation of proteins that are key players in cellular signaling and organization. By targeting a protein like ANKRD37, these inhibitors provide insights into the sophisticated mechanisms of protein-protein interactions and cellular communication. The development of these inhibitors contributes to a deeper understanding of the molecular mechanisms underlying cellular processes, offering a foundation for exploring the regulation of protein interactions and signaling at the molecular level. Furthermore, the study of ANKRD37 inhibitors highlights the complexity of targeting specific protein functions within the intricate framework of cellular systems. It serves as a pathway to more comprehensive knowledge of cellular dynamics, shedding light on the nuanced interactions that dictate cellular behavior and responses.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib, a proteasome inhibitor, could possibly inhibit ANKRD37 by preventing the degradation of proteins, potentially affecting its stability and function.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

As a kinase inhibitor, Staurosporine might inhibit ANKRD37 by impacting kinase-dependent signaling pathways, potentially altering its activity.

Calyculin A

101932-71-2sc-24000
sc-24000A
sc-24000B
sc-24000C
10 µg
100 µg
500 µg
1 mg
$160.00
$750.00
$1400.00
$3000.00
59
(3)

Calyculin A, a phosphatase inhibitor, could inhibit signaling processes that affect ANKRD37's function.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Trichostatin A, an HDAC inhibitor, might influence gene expression, potentially affecting ANKRD37's role in protein interactions.

Geldanamycin

30562-34-6sc-200617B
sc-200617C
sc-200617
sc-200617A
100 µg
500 µg
1 mg
5 mg
$38.00
$58.00
$102.00
$202.00
8
(1)

Geldanamycin, an HSP90 inhibitor, might affect the folding and stability of proteins like ANKRD37.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

Ruxolitinib, a JAK/STAT inhibitor, could influence signaling pathways that involve ANKRD37.

BAY 11-7082

19542-67-7sc-200615B
sc-200615
sc-200615A
5 mg
10 mg
50 mg
$61.00
$83.00
$349.00
155
(1)

BAY 11-7082, an NF-κB pathway inhibitor, might impact pathways where ANKRD37 is involved.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002, a PI3K/Akt inhibitor, could influence ANKRD37's role in PI3K/Akt signaling pathways.

XAV939

284028-89-3sc-296704
sc-296704A
sc-296704B
1 mg
5 mg
50 mg
$35.00
$115.00
$515.00
26
(1)

XAV-939, targeting the Wnt/β-Catenin pathway, could impact ANKRD37's involvement in this signaling pathway.

Cytochalasin D

22144-77-0sc-201442
sc-201442A
1 mg
5 mg
$145.00
$442.00
64
(4)

Cytochalasin D, affecting cytoskeletal dynamics, might influence ANKRD37 in cytoskeletal organization.